Moreover, very recently montelukast, a potent CysLT1-R antagonist clinically used in the therapy of asthma [16,17], has been demonstrated to inhibit allergen-induced airway remodeling in an in vivo mouse model of asthma [18]. The gene discussed is CYSLTR1; the disease is asthma.